

Using HLA Typing to Subgroup Patients Could Be an Important Tool in CFS and MCS Research

by Laurie Dennison Busby, BEd

Notes

1. Morris, G., Maes, M. Case definitions and diagnostic criteria for myalgic encephalomyelitis and chronic fatigue syndrome: from clinical-consensus to evidence-based case definitions. *Neuro Endocrinol Lett* 2013;34(3):185-99.
2. Keller, R.H., Lane, J.L., Klimas, N., Reiter, W.M., Fletcher, M.A., van Riel, F., Morgan, R. Association between HLA Class II antigens and the chronic fatigue immune dysfunction syndrome. *Clin Infect Dis* 1994; 18(Suppl I):s154-6.
3. Carlo-Stella, N., Bozzini, S., De Silvestri, A., Sbarsi, I., Pizzochero, C., Lorusso, L., Martinetti, M., Cuccia, M. Molecular study of receptor for advanced glycation endproduct gene promotor and identification of specific HLA haplotypes possibly involved in chronic fatigue syndrome. *Int J Immunopathol Pharmacol* 2009;22(3):745-54.
4. Ortega-Hernandez, O.D., Cuccia, M., Bozzini, S., Bassi, N., Moscovitch, S. et al. Autoantibodies, polymorphisms in the serotonin pathway, and human leukocyte antigen class II alleles in chronic fatigue syndrome: are they associated with age at onset and specific symptoms? *Ann NY Acad Sci* 2009;1173:589-99. doi: 10.1111/j.1749-6632.2009.04802.x.
5. Helbig, K.J., Heatley, S.L., Harris, R.J., Mulligan, C.G., Bardy, P.G., Marmion, B.P. Variation in immune response genes and chronic Q fever. Concepts: preliminary test with post-Q fever fatigue syndrome. *Genes and Immunity* 2003;4:82-5. doi: 10.1038/sj.gene.6363912.
6. Spitzer, A.R., Broadman, M. A retrospective review of the sleep characteristics in patients with chronic fatigue syndrome and fibromyalgia. *Pain Pract* 2010;10(4):294-300. doi: 10.1111/j.1533-2500.2009.00352.x.
7. Smith J., Fritz E.L., Kerr J.R., Cleare A.J., Wessely S., Matthey D.L. Association of chronic fatigue syndrome with human leucocyte antigen class II alleles. *J Clin Pathol*. 2005; 58(8):860-3. doi: 10.1136/jcp.2004.022681.
8. Underhill, J., Mahalingam, M., Peakman, M., Wessely, S. Lack of association between HLA genotype and chronic fatigue syndrome. *Eur J Immunogenet* 2001;28(3):425-8. doi: 10.1046/j.1365-2370.2001.00235.x.
9. Katahira, M., Segawa, S., Maeda, H., Yasuda, Y. Effect of human leukocyte antigen class II genes on acute-onset and slow-onset type 1 diabetes in the Japanese population. *Hum Immunol* 2010;71(8):789-94. doi: 10.1016/j.humimmun.2010.05.020.
10. Zeitlin, A.A., Heward, J.M., Newby, P.R., Carr-Smith, J.D., Franklyn, J.A., Gough, S.C., Simmonds, M.J. Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' disease. *Genes Immun* 2008;9(4):358-63. doi: 10.1038/gene.2008.26.
11. Carlquist, J.F., Menlove, R.L., Murray, M.B., O'Connell, J.B., Anderson, J.L. HLA class II (DR and DQ) antigen association in idiopathic dilated cardiomyopathy: validation study and meta-analysis of published HLA association studies. *Circulation* 1991; 83: 515. doi:10.1161/01.CIR.83.2.515.
12. Alaez, C., Lin, L., Flores-A, H., Vazquez, M., Munguia, A. Association of narcolepsy-cataplexy with HLA-DRB1 and DQB1 in Mexican patients: A relationship between HLA and gender is suggested. *BMC Medical Genetics* 2008;9:79. doi:10.1186/1471-2350-9-79.
13. Ettinger, R.A., Kwok, W.W. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. *J Immunol* 1998;160(5):2365-73.
14. Janegova, A., Janega, P., Rychly, B., Kuracinova, K., Babal, P. The role of Epstein-Barr virus infection in the development of autoimmune thyroid diseases. *Endokrynol Pol* 2015;66(2):132-6. doi: 10.5603/EP.2015.0020.
15. Tajiri, K., Yasutomi, Y., Aonuma, K. Recent advances in the management of autoimmune myocarditis: insights from animal studies. *Curr Pharm Des* 2015
16. Nijs, J., De Becker, P., De Meirleir, K., Demanet, C., Vincken, W., Schuermans, D., McGregor, N. Associations between bronchial hyperresponsiveness and immune cell parameters in patients with chronic fatigue syndrome. *Chest* 2003;123(4):998-1007.
17. Lerner, A.M., Zervos, M., Chang, C.H., Beqaj, S., Goldstein, J. et al. A small randomized, placebo-controlled trial of the use of antiviral therapy of patients with chronic fatigue syndrome. *Clin Infect Dis* 2001;32:1656-7.
18. Nisenbaum, R., Jones, J.F., Unger, E.R., Reyes, M., Reeves, W.C. A population-based study of the clinical course of chronic fatigue syndrome. *Health Qual Life Outcomes* 2003;1:49.
19. Mawle, A.C., Nisenbaum, R., Dobbins, J.G., Gary, H.E. Jr, Stewart, J.A. et al. Immune responses associated with chronic fatigue syndrome: a case-control study. *J Infect Dis* 1997;175(1):136-41.
20. Trevino, A., Vicario, J.L., Lopez, M., Parra, P., Benito, R. et al. Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. *J Neurol* 2013;260(10):2551-5.
21. Rossman, M.D., Thompson, B., Frederick, M., Iannuzzi, M.C., Rybicki, B.A. HLA and environmental interactions in sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis* 2008;25(2):125-32.
22. Wang, Z., White, P.S., Petrovic, M., Tatum, O.L., Newman, L.S., Maier, L.A., Marrone, B.L. Differential susceptibilities to chronic beryllium disease contributed by different Glu 69 HLA-DPB1 and DPA1 alleles. *J Immunol* 1999;163(3):1647-53.
23. Watson, N.F., Ton, T.G.N., Koepseli, T.D., Gersuk, V.H., Longstreth Jr., W.T. Does narcolepsy symptom severity vary according to-HLA-DQB1*0602 allele status? *Sleep* 2010;33(1):29-35.
24. Gonzales-Gay, M.A., Garcia-Porrucua, C., Hajeer, A.H. Influence of human leukocyte antigen-DRB1 on susceptibility and severity of rheumatoid arthritis. *Semin Arthritis Rheum* 2002;31(6):355-60.
25. Viatte, S., Plant, D., Han, B., Fu, B., Yarwood, A. et al. Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. *JAMA* 2015;313(16):1645-56. doi: 10.1001/jama.2015.3435.
26. Han, B., Diogo, D., Eyre, S., Kallberg, H., Zhernakova, A. et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. *Am J Human Genet* 2014;94(4):522-32. doi: 10.1016/j.ajhg.2014.02.013.